Introduction
Tumor suppressor genes are able to limit premalignant cell proliferation by a variety of mechanisms, most notably by the induction of growth arrest or apoptosis.
Activation of protein kinase C (PKC)-d, a widely expressed PKC isoform, can induce growth arrest in several cell types (Watanabe et al., 1992; Griffiths et al., 1996; Black, 2000; Frey et al., 2001) . In addition, the cleavage and activation of PKC-d is both necessary and sufficient for apoptosis induced by UV light in normal human keratinocytes (Denning et al., 1998 (Denning et al., , 2002 D'Costa and Denning, 2005) . PKC-d is activated proteolytically by caspase-3-mediated cleavage in human keratinocytes (Denning et al., 1998) , as well as many other cell types undergoing apoptosis (Emoto et al., 1995; Ghayur et al., 1996; Reyland et al., 2000; Cataldi et al., 2002) . Since apoptosis can be a protective mechanism from UV-induced skin cancer, PKC-d activation may participate in the elimination of precancerous cells by promoting apoptosis (Ziegler et al., 1994; Jiang et al., 1999) . Indeed PKC-d has tumor suppressor properties in mouse skin since PKC-doverexpressing transgenic mice are resistant to skin chemical carcinogenesis, and treatment of mouse keratinocytes overexpressing PKC-d with the tumor promoter TPA triggers apoptosis (Li et al., 1999; Reddig et al., 1999) . The PKC-d inhibitor rottlerin induces a transformed phenotype in HaCaT cells (Dietrich et al., 2001) , and PKC-d acts as a tumor suppressor in other cell types such as transformed colon epithelial and fibroblast cell lines Perletti et al., 1999) .
The expression of activated Ha-ras in mouse keratinocytes induces tyrosine phosphorylation and enzymatic inhibition of PKC-d, and has been linked to a reduced differentiated phenotype (Denning et al., 1993 (Denning et al., , 1996 Joseloff et al., 2002) . In addition, PKC-d protein and activity are lost in chemically induced mouse skin tumors, where activating Ha-ras mutations are initiating events (Roop et al., 1986; Reddig et al., 1999) . While ras gene mutations are found in 58% of human squamous cell carcinomas (SCCs) (Pierceall et al., 1991) , it is not known if the proapoptotic PKC-d is lost in human SCCs. In the HaCaT human keratinocyte cell line, expression of activated Ha-ras selectively reduces PKCd protein and mRNA levels without affecting other PKC isoform levels, and loss of PKC-d in rastransformed HaCaT cells is mediated by transforming growth factor (TGF)-a/epidermal growth factor receptor (EGFR) signaling (Geiges et al., 1995) . Autocrine TGF-a/EGFR signaling is also responsible for the tyrosine phosphorylation and enzymatic inhibition of PKC-d in ras-transformed mouse keratinocytes (Denning et al., 1996) . Thus, loss of PKC-d protein and/or activity is a common feature of ras-transformed skin tumors. In addition, inhibition of PKC-d by rottlerin or a dominant/negative PKC-d transforms EGFR-overexpressing rat 3Y1 fibroblasts in the absence of epidermal growth factor (EGF), further implicating PKC-d as a suppressor of EGFR-dependent cell transformation (Hornia et al., 1999) .
The human PKC-d gene is located at chromosome 3p21.31, and this region is frequently lost in poorly differentiated SCCs and in 60% of Bowen's disease, as determined by interphase FISH and comparative genomic hybridization (Dobler et al., 1999; Popp et al., 2000 Popp et al., , 2002 . Thus, in addition to the loss of PKC-d expression in ras-transformed keratinocytes via a TGFa/EGFR autocrine loop, the PKC-d gene may be frequently deleted in SCCs.
In this study, we re-expressed PKC-d in human HaCaT cells expressing activated ras (HaCaT Ras II-4 cells), and found that PKC-d induced apoptosis and suppressed tumor formation in nude mice. We also evaluated the expression of PKC-d in human skin SCCs, Bowen's disease, and normal human skin by immunohistochemical staining, and found that PKC-d was lost in 12/42 (29%) of human skin cancers evaluated. These results indicate that the loss of PKC-d expression is important for ras-mediated transformation, and supports a role of PKC-d as a tumor suppressor in human skin SCCs.
Materials and methods

Immunohistochemistry
Tissue samples were fixed in 10% neutral buffered formalin and embedded in paraffin. Tissue sections were deparaffinized followed by antigen retrieval (10 mM citrate buffer, pH 6.0, microwave 500 W; 15 min). The samples were stained for PKCd (sc-937, 1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA), PCNA (BD Transduction Laboratories, Palo Alto, CA, USA 1:50), or active caspase-3 (R&D Systems, 1:500) by immunohistochemical methods using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). The level of PKC-d staining was evaluated throughout the entire tumor section, and was classified as having lost PKC-d if greater than 50% of the tumor cells had low reactivity that was comparable to the blocking peptide control. The tissue samples were also stained for phospho-EGFR (Y1068) (2236, Cell Signaling Technology Inc., Beverly, MA, USA) at a dilution of 1:100 overnight. To avoid any potential bias, the person reading the phospho-EGFR-stained tumors was blinded to the PKC-d status of the tumor. All human tissue samples were obtained with approval from the Loyola University Medical Center's Institutional Review Board.
Virus construction
A retrovirus encoding PKCd was constructed by cloning the full-length human PKC-d cDNA (80048, American Tissue Culture Collection, Manassas, VA, USA) into the XbaI site of pBluescript KS (Denning et al., 2002) , digesting it with KasI/ BamHI to remove the initiation codon, and replacing it with double-stranded oligonucleotides encoding a Kozak sequence and an amino-terminal c-myc epitope tag to generate pKSmyc-PKCd-1. The myc-tagged PKC-d was removed by digesting with BamHI/NotI, and cloned into the BamHI/NotI sites of LZRS (Paul Khavari, Stanford University School of Medicine, Stanford, CA, USA) to generate LZRS-myc-PKCd. Active Ras (Q61) virus was constructed by inserting Ras (Q61) into the BamHI/XhoI sites of LZRS-Linker, and the dominant/negative PKCd(K378A) was described previously (Denning et al., 2002; D'Costa and Denning, 2005) . Retroviruses were generated by transfecting plasmids with calcium phosphate into the Phoenix Ampho retroviral packaging line (ATCC with permission Garry P Nolan, Stanford University Medical Center) and selecting with puromycin. Viruses were harvested from confluent dishes cultured at 321C for 24-48 h. As a negative control, virus was generated from the empty LZRS-Linker vector (Denning et al., 2002) .
Cell culture and retroviral infection
HaCaT, HaCaT Ras I-7, and HaCaT Ras II-4 cells (kindly provided by Norbert Fusenig and Mihaela Skobe) were grown in DMEM with 10% FBS. All cells were infected twice with Linker virus or PKC-d virus by spin infections in six well dishes. The level of overexpression of PKC-d was measured by flow cytometry prior to injection into nude mice and confirmed by Western blotting for PKC-d. For some experiments, HaCaT cells were treated with EGF at 10 ng/ml for 2 days.
Growth assays
HaCaT and HaCaT Ras II-4 cells were plated at a density of 1 Â 10 5 per well in six well dishes, and infected the next day twice with either Linker virus or PKC-d virus. Viable cells were counted by trypan blue staining. Data from the HaCaT Ras II-4 growth curve in Figure 2c were fitted to an exponential curve using Microsoft Excel (R 2 ¼ 0.9996). Using the equation describing HaCaT Ras II-4 cell growth [y ¼ (starting cell number)e 0.4557x ], where x equals the number of days, a new theoretical growth curve was calculated by subtracting 6% of the cell number per day, starting with day 1, and using the adjusted cell yield as the starting cell number for the next day's calculation. Thus, the calculated growth curve represents the growth rate of HaCaT Ras II-4 cell if they lost 6% of their cell number every day due to apoptosis.
Flow cytometry
The levels of PKC-d overexpression in nude mice were analysed by flow cytometry prior to injection. Cell cycle analysis of HaCaT Ras II-4 cells infected with empty Linker or PKC-d virus was performed by propidium iodide staining and flow cytometry as described previously (Denning et al., 1998) . The cells were washed twice with PBS and fed the day after infection, and then assayed 2 days after infection.
Tumor growth in nude mice
Athymic male (BALB/c) nude mice were obtained from Taconic (Germantown, NY, USA) and housed in laminar airflow cabinets under pathogen-free conditions with a 12 h light/12 h dark cycle. The mice were injected subcutaneously on either side with 5 Â 10 6 cells in 200 ml per injection and the growth of tumors measured twice a week over 21 days. Tumor volume was calculated using the formula length Â width Â height, as measured using calipers.
Western blotting
Total cell lysates from cultured cells were prepared by lysing cells in 20 mM Tris-HCl, pH 7.5, 1% Triton X-100, and 1 Â Complete Protease Inhibitor Cocktail (Boehringer Mannheim, Indianapolis, IN, USA). For tumor lysates, freshly harvested tissues samples were homogenized in ice-cold CHAPS buffer (20 mM Hepes, pH 7.4, 140 mM NaCl, 10 mM CHAPS, 2 mM EDTA, 1 mM EGTA, and Complete Protease Inhibitor Cocktail), and incubated on the thermoshaker for 30 min at 41C. Lysates were spun in a microcentrifuge for 10 min at 41C, and 20 mg protein from the supernatant taken for analysis. The proteins were run on SDS-polyacrylamide gels, transferred to nitrocellulose, and stained with Ponceau S to ensure equal protein loading. The membranes were blocked with 5% milk in 20 mM Tris-HCl, pH 7.6, 150 mM NaCl (TBS), stained with primary antibody and horseradish peroxidase-conjugated secondary antibody for 1 h each, and extensively washed in TBS, 0.05% Tween-20. Proteins were detected using the ECL detection kit (Amersham Life Sciences, Piscataway, NJ, USA). PKC-a (sc-208, 1:1000), PKC-d (sc-937, 1:4000), PKC-e (sc-214, 1:200), PKC-Z (sc-215, 1:200), and PKC-z (sc-216, 1:1000) were detected by Western blotting using rabbit antibodies from Santa Cruz Biotech. An actin antibody (ICN Biomedicals Inc., Irvine, CA, USA) used at a dilution of 1:4000 served as a control for equal loading.
Results
PKC-d levels are decreased in human keratinocytes
expressing active ras PKC-d protein and mRNA are reported to be selectively lost in two ras-transfected and clonally selected human keratinocyte cell lines, HaCaT Ras I-7 and HaCaT Ras II-4 (Boukamp et al., 1990; Geiges et al., 1995) . In Figure 1b , we found that PKC-d protein levels were reduced but still detectable in HaCaT Ras I-7 and II-4 cells. In addition, Figure 1a shows that PKC-d levels were decreased in a mass population of HaCaT cells infected with an active Ha-ras (Q61) retrovirus, indicating that the ras-induced loss of PKC-d is not due to clonal variation. HaCaT cells treated with EGF also had a loss of PKC-d protein (Figure 1b ), confirming that EGFR signaling is involved in the loss of PKC-d (Geiges et al., 1995; Denning et al., 1996) . Using retroviral transduction, the full-length wild-type PKC-d was reexpressed in a mass population of HaCaT Ras II-4 cells, as shown in Figure 1a (lane 4). As shown in Figure 1c , the levels of PKC-a, PKC-e, and PKC-z were not significantly different between HaCaT and HaCaT Ras II-4 cells, consistent with previous results (Geiges et al., 1995) . Furthermore, PKC-d overexpression did not alter the levels of other PKC isoforms. PKC-Z was not detected as PKC-Z is only expressed in differentiating keratinocytes (data not shown) (Koizumi et al., 1993; Osada et al., 1993) . PKC-d re-expression was also determined by FACS analysis for rapid monitoring of expression levels (data not shown). PKC-d was routinely overexpressed 10-fold above the Linker-infected control HaCaT Ras II-4 cells.
Growth inhibition and induction of apoptosis in HaCaT Ras II-4 cells overexpressing PKC-d
In addition to downregulating PKC-d levels, expression of activated ras triggers the activation of multiple mitogenic and survival pathways (Raf/MAPK, PI3K/ Akt, RalGDS/Ral) (Ewen, 2000) . To determine if the downregulation of PKC-d in tumorigenic HaCaT Ras II-4 cells was required for their enhanced growth rate and transformed phenotype, we restored the expression of PKC-d in HaCaT Ras II-4 cells by retroviral transduction and analysed their growth properties. Table 1 .
Since apoptosis was found to be partially responsible for PKC-d-induced growth inhibition in culture, we examined the tumors and cysts recovered from nude mice for markers of apoptosis (active caspase-3) and cell proliferation (PCNA). As shown in Figure 6 , the cysts formed by the parental HaCaT cells had rare cells with active caspase-3, even in areas of morphological terminal differentiation. In addition, only rare isolated cells in the Linker-infected HaCaT Ras II-4 tumors were undergoing apoptosis, as detected by active caspase-3 staining. In contrast, all the PKC-d-infected HaCaT Ras-II-4 tumors had extensive areas of active caspase-3 staining, indicating a much higher apoptotic rate. Surprisingly, PCNA-positive nuclei were also much more prevalent in the PKC-d-infected HaCaT Ras II-4 Tumors from nude mice were stained with hematoxylin and eosin and classified as either cysts or SCCs. Shown is the type of cell and the virus transduced. The numbers indicated the number of injection sites that produced either no tumor, a benign cyst, or a SCC over the total number of injection sites. 
Tumor suppression by PKC-d in skin cancers
Loss of PKC-d in human SCCs
The loss of PKC-d in ras-transformed HaCaT cells and chemically induced mouse papillomas (Geiges et al., 1995; Reddig et al., 1999) , plus the ability of PKC-d to induce growth arrest (Watanabe et al., 1992; Griffiths et al., 1996) and apoptosis (Li et al., 1999; Denning et al., 2002; Efimova et al., 2004; Sitailo et al., 2004) , prompted us to explore the potential loss of PKC-d in human SCCs. Normal human skin was stained for PKC-d and 6/6 (100%) samples were positive for PKCd, as shown in Figure 7a . The staining for PKC-d in normal skin was stronger in the basal layer, but was seen in all layers and could be completely prevented by preincubation of the antibody with a blocking peptide. Bowen's disease samples and one solar keratosis (data not shown), both precancerous lesions, indicating that loss of PKC-d can be an early event in human skin carcinogenesis. The loss of PKC-d observed by immunohistochemistry was confirmed by Western blotting in an independent group of tumors. Figure 7b shows three randomlyselected human SCC tumors that had almost complete loss of PKC-d. For patient 3, matched normal skin was also analysed and had abundant PKC-d levels. As a loading control, actin levels were also assessed and were not different between the tumor lysates.
Since EGFR signaling is linked to the loss of PKC-d in both human and mouse keratinocytes (Geiges et al., 1995; Denning et al., 1996) , we also stained SCCs with PKC-d loss for phospho-EGFR as an indicator of activated EGFR signaling. As shown in Figure 7c , while normal skin gave no membrane reactivity for phospho-EGFR, several of the tumors (five of eight, 62%) that had reduced PKC-d also had membrane phospho-EFGR staining. Although the overall intensity of phospho-EGFR staining varied among normal and tumor samples, membrane staining was restricted to the SCCs and was not detected in normal human skin. Thus, the majority of human SCCs that have lost PKC-d immunoreactivity also have activated (autophosphorylated) EGFR, consistent with the role for EGFR signaling in PKC-d loss identified in cell culture studies (Figure 1 ; Geiges et al., 1995; Denning et al., 1996) .
Discussion
Our data support a role for PKC-d as a tumor suppressor in human SCCs of the skin, and is the first description of the loss of PKC-d in human SCCs. The general properties of a tumor suppressor are its ability to induce apoptosis, trigger growth arrest and/or differentiation, and its loss in malignant and premalignant tumors (Sherr, 2004) . PKC-d fulfills these criteria since it is necessary and sufficient for UV apoptosis (Denning et al., 1998; Li et al., 1999; Leitges et al., 2001; Sitailo et al., 2004; D'Costa and Denning, 2005) , can cause cell cycle arrest (Watanabe et al., 1992; Perletti et al., 1999) , and can induce keratinocyte differentiation marker expression (Deucher et al., 2002) . We found that re-expression of PKC-d in ras-transformed HaCaT cells induces a moderate level of apoptosis (Figure 3 ), but this level of apoptosis compounded daily can dramatically inhibit overall cell growth and is sufficient to account for the growth-suppressive effects of PKC-d (Figure 2c ). In addition, we partially reversed PKC-d growth inhibition by expressing the antiapoptotic Bcl-2 family member Bcl-x L .
Ectopic expression of tumor suppressors can also inhibit tumor formation, and transgenic mice overexpressing PKC-d are resistant to skin tumor promotion by chemical carcinogens (Reddig et al., 1999) . A recent study also demonstrated that overexpressing PKC-d in HaCaT cells suppressed tumor formation in SCID mice (Papp et al., 2004) We also found that PKC-d was lost in B30% of the human skin tumors that we studied ( Table 2) . The loss or inactivation of PKC-d in human tumors is a prerequisite for it being a tumor suppressor in human skin carcinogenesis. The loss of PKC-d in human skin cancers helps validate mouse models of chemical skin carcinogenesis where loss of PKC-d has been previously observed (Reddig et al., 1999; Wheeler et al., 2002) .
Keratinocytes express five PKC isoforms (a, d, e, Z, and z) which have selective roles in skin carcinogenesis, functioning to enhance (i.e. PKC-e) or suppress (i.e. PKC-d, PKC-Z) tumor formation (Reddig et al., 1999 (Reddig et al., , 2000 Jansen et al., 2001; Chida et al., 2003; Wheeler et al., 2003 Wheeler et al., , 2004 Wheeler et al., , 2005 Papp et al., 2004) . While there is selective loss of PKC-d in ras-transformed HaCaT cells, loss of PKC-e has been reported in both mouse and human SCCs (Wheeler et al., 2005) , and thus multiple PKC isoform changes can occur during multi-step skin carcinogenesis.
The mechanism of PKC-d loss in human SCCs is unknown, but is likely to involve ras/EGFR signaling. Ras activation has been reported in B50% of human SCC (Pierceall et al., 1991) , and keratinocytes with active ras mutation secrete autocrine EGFR ligands such as TGF-a (Glick et al., 1991; Dlugosz et al., 1995) . EGFR is required to maintain the proliferative population in the basal compartment of epidermal tumors (Hansen et al., 2000) , and it provides an essential survival signal for skin tumor development (Sibilia et al., 2000) . Furthermore, disruption of the EGFR receptor impairs the growth of squamous papillomas expressing the v-Ha-ras oncogene (Dlugosz et al., 1997) . Membrane Tumor suppression by PKC-d in skin cancers AM D'Costa et al staining for phospho-EGFR was seen in the majority of human SCC tumors which had lost PKC-d (Figure 7c ), suggesting activation of the ras/TGF-a/EGFR autocrine feedback loop. Several studies have identified autocrine TGF-a and the EGFR as being necessary for the inhibition/loss of PKC-d in neoplastic keratinocytes (Geiges et al., 1995; Denning et al., 1996) . In addition, Src family tyrosine kinases can phosphorylate PKC-d in response to EGFR activation and lead to inhibition or downregulation of PKC-d (Denning et al., 1996; Zang et al., 1997; Joseloff et al., 2002) . The exact mechanism of how PKC-d is reduced in human SCC tumors with active ras/EGFR signaling is still unknown; however, HaCaT Ras I-7 and HaCaT Ras II-4 cells have lost PKC-d mRNA expression, and thus inhibition of PKCd transcription may play a role in ras-transformed keratinocytes (Geiges et al., 1995) . Chromosome loss at 3p21.31, where the human PKC-d gene resides, is frequent in human SCC, and may explain the loss of PKC-d in the subset of SCCs without activated ras/ EGFR signaling (Dobler et al., 1999; Ashton et al., 2003) . The loss of PKC-d in ras-transformed keratinocytes was specific as no changes in other PKC isoforms were observed (Figure 1c ) (Geiges et al., 1995) . Furthermore, there was no compensatory increase in other PKC isoforms in the epidermis of PKC-d null mice (Wheeler et al., 2002) . The tumor suppression mechanism of PKC-d is likely to involve the induction of apoptosis. We found that reexpression of PKC-d in HaCaT Ras II-4 cells inhibited the growth and increase apoptosis, both in culture (Figures 2 and 3 ) and in nude mice (Figure 4) . Furthermore, the growth inhibition in culture could be partially reversed by overexpressing the antiapoptotic protein Bcl-x L . Bcl-x L did not significantly enhance the growth rate of mock-infected HaCaT cells or HaCaT Ras II-4 cells, indicating that Bcl-x L was not stimulating growth in the absence of high PKC-d levels. Finally, we observed B6% increase in apoptotic cells over a 24-h period (Figure 3 ). While this increase in apoptosis is modest, it can entirely explain the growth suppression observed in Figure 2 .
The mechanism of PKCd-induced apoptosis has been extensively studied, and involves components of the intrinsic death effector pathway (Brodie and Blumberg, 2003) . Expression of the PKC-d catalytic fragment, which is generated by caspase-3 cleavage in response to UV radiation and other apoptotic stimuli, has been associated with both the mitochondria and nucleus (Denning et al., 2002; DeVries et al., 2002) . Kinase activity is required for PKC-d to induce apoptosis, and several apoptotic substrates for the PKC-d catalytic fragment have been identified, including lamin B, phospholipid scramblase 1 and 3, DNA-dependent protein kinase, Rad9, p73b, and p38d (Bharti et al., 1998; Cross et al., 2000; Frasch et al., 2000; Ren et al., 2002; Liu et al., 2003; Yoshida et al., 2003; Efimova et al., 2004) . Despite the identification of these substrates, how the PKC-d catalytic fragment initiates the activation of Bax, release of cytochrome c, and activation of multiple caspases is unclear (Sitailo et al., 2004) . Studies overexpressing the full-length PKC-d and activating with TPA have also found mitochondrial death effector pathway activation (Li et al., 1999; Fujii et al., 2000) . Although the full-length PKC-d we expressed was wild type, spontaneous activation can occur, and ras-transformed keratinocytes have elevated cellular diacylglycerol, an endogenous activator of PKC isoforms (Lee et al., 1992) . Surprisingly, we also found elevated PCNA staining in HaCaT Ras II-4 tumors expressing PKC-d (Figure 6 ). Enhanced proliferation in tumors with enhanced apoptosis has also been reported for human SCC (Einspahr et al., 1999) , and this strong correlation between proliferation and apoptosis suggests that the elevated apoptotic rate is driving increased proliferation in these tumors. It is also possible that the cells capable of forming tumors or cysts have somehow overcome the PKC-d-induced growth inhibition, perhaps by acquiring additional growth-promoting mutations. Despite the enhanced PCNA staining in the HaCaT Ras II-4 tumors with PKC-d, the tumors that did form were much smaller and most were benign cysts, indicating that the enhanced proliferation could not completely compensate for the elevated apoptotic rate.
Re-expression or activation of residual proapoptotic PKC-d in SCC tumors has a potential therapeutic application. Pharmacological reversal of PKC-d downregulation in neoplastic keratinocytes may be possible with inhibitors of EGFR signaling or Src activity, and the re-expression of PKC-d could cause an inhibition of cell growth and induction of apoptosis. A small increase in apoptotic rate can cause relatively large growthinhibitory effects in regressing skin tumors (Burns et al., 1976) , and our results have demonstrated that even a modest increase in apoptosis induced by PKC-d reexpression can inhibit the growth of transformed human keratinocytes. In summary, our findings establish the proapoptotic function of PKC-d as a tumor suppressor mechanism that may be functioning in the pathogenesis of human SCCs.
Abbreviations SCC, squamous cell carcinoma; PKC-d, protein kinase Cdelta; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; TGF-a, transforming growth factoralpha.
